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The purpose of this study was to build a prognostic model of hepatocellular carcinoma (HCC) using 
time-dependent covariates to re-evaluate the prognosis at any stage of the disease.  The subjects were 
consecutive HCC patients who were treated at our institute between 1995 and 2007.  We constructed 
time-ﬁxed and time-dependent prognostic models with a training group (n＝336) and compared the 
prognostic abilities between conventional Cancer of the Liver Italian Program (CLIP) scores,  Japan 
Integrated Staging (JIS) scores,  an Okuda classiﬁcation,  and our prognostic models in the testing 
group (n＝227) with the c-index.  The time-dependent prognostic model consisted of main tumor size,  
tumor number,  portal vein invasion,  distant metastasis,  alpha-fetoprotein,  des-gamma-carboxy pro-
thrombin (DCP),  bilirubin,  and albumin and the weighted scores were set for each factor depending 
on the hazard ratio for the prognosis.  The prognostic index was determined by summing the scores.  
The c-index values for the CLIP scores,  JIS scores,  Okuda classiﬁcation,  and our time-dependent 
model were 0.741,  0.727,  0.609,  and 0.870,  respectively.  These results indicate that our time-dependent 
model can estimate the prognosis of HCC more precisely than traditional time-ﬁxed models and can be 
used to re-predict the prognosis of HCC.
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epatocellular carcinoma (HCC) is the ﬁfth most 
common cancer and is one of the leading causes 
of cancer death in the world [1].  In Japan,  approxi-
mately 35,000 people die of HCC every year,  and 
90ｵ of patients suﬀer from persistent infection of 
hepatitis B virus (HBV) or hepatitis C virus (HCV) 
[2].
　 The prognosis is aﬀected by both the tumor sever-
ity,  as indicated by factors such as size and the num-
ber or levels of alpha-fetoproteins (AFP),  and the 
degree of pre-existing liver damage,  as indicated by 
serum albumin or serum bilirubin levels [3].  Many 
prognostic models of HCC using Cox regression mod-
els have been described.  As for uniﬁcation scores to 
estimate prognosis,  the Child-Pugh stage [4],  the 
Cancer of the Liver Italian Program (CLIP) score 
[5],  the Japan Integrated Staging (JIS) score [6],  
and the Barcelona Clinic and Liver Cancer (BCLC) 
classiﬁcation [7] have been reported.  However,  most 
of these prognostic models are based on tumor-related 
H
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factors and background factors at the initial treatment 
of HCC.
　 Recently,  time-dependent analyses using repeti-
tively measured prognostic variables have been 
reported and their usefulness has been suggested 
[8-11].  Boberg et al.  have reported that the predic-
tion of prognosis improves when the change in a 
covariate over time is included in the prognostic index 
of primary sclerosing cholangitis [8].  Murtaugh et al.  
have developed an updated model for primary biliary 
cirrhosis that can be used to predict short-term sur-
vival at any time in the course of the disease [11].
　 HCC frequently recurs even after curative treat-
ments such as hepatectomy or radiofrequency ablation 
(RFA).  Stage and the liver residual function at recur-
rence of tumor may often vary in patients whose 
prognoses have been predicted to be the same by con-
ventional methods.  Therefore,  re-evaluation of prog-
nosis after initial treatment is a rational way of 
achieving a better prediction of survival.
　 The purpose of this study was to build a prognostic 
model of HCC using time-dependent covariates,  which 
we can then use to re-evaluate the prognosis at any 
stage of the disease.
Materials and Methods
　 Patients. We examined 563 consecutive 
patients who were newly diagnosed as having HCC and 
received initial treatment of HCC at Okayama 
University Hospital from January,  1995 to June,  
2007.  We divided the patients into a training group (n
＝336) and a testing group (n＝227).  Patients for 
whom the last digit of their identiﬁcation data (ID) 
number was 0-5 were assigned to the training group,  
regardless of condition,  and those for whom the last 
digit was 6-9 was assigned to the testing group.  We 
built prognostic models with the training group and 
validated them with the testing group.  The patients 
who were alive at the end of June,  2007 were no lon-
ger followed in the study and were assumed considered 
to be “censored”.  The average observation period was 
3.0 years.  Informed consent was obtained from 
patients for the use of their clinical data.  The study 
protocol conformed to the ethical guidelines of the 
World Medical Association Declaration of Helsinki,  
and was approved by the ethical committee of the 
institute.
　 Diagnosis. HCC was diagnosed by abdominal 
ultrasonography,  abdominal computerized tomography 
(CT),  magnetic resonance imaging (MRI),  abdominal 
angiography or tumor biopsy.  The diagnostic criteria 
for HCC via imaging were based on previous reports 
of hyperattenuation at the arterial phase,  hypoattenu-
ation at the portal phase in dynamic CT or MRI,  and 
tumor staining on angiography [12].  The patients with 
hepatic masses who did not satisfy the above criteria 
underwent ultrasound-guided ﬁne-needle biopsy with 
histologically conﬁrmed HCC.  We classiﬁed HCC 
morphologically according to the criteria outlined by 
the Liver Cancer Study Group of Japan [13].
　 Treatments. The selection of therapies was 
performed in accordance with the evidence-based 
clinical practice guidelines for HCC in Japan [14].
　 For the initial treatment of HCC,  150 (27ｵ),  
129 (23ｵ),  and 73 patients (13ｵ) received RFA,  
hepatectomy,  and percutaneous ethanol injection 
therapy (PEIT),  respectively (Table 1).  One hundred 
and thirty-one people (23ｵ) underwent transcatheter 
arterial chemoembolization (TACE)/transcatheter 
arterial infusion (TAI) without local ablation thera-
pies.  TACE/TAI was performed before PEIT and 
RFA in 36ｵ (26/73) and 66ｵ (99/150) of the 
patients,  respectively.
　 Follow-up. We performed blood tests at every 
outpatient visit (at least once every 3 months).  The 
examined factors were as follows: bilirubin,  serum 
albumin,  aspartate aminotransferase (AST),  alanine 
aminotransferase (ALT),  serum creatinine,  platelet 
count,  prothrombin time and tumor markers (AFP and 
des-gamma-carboxy prothrombin,  DCP).  Ultrasound,  
dynamic CT,  or MRI were also performed every 3-4 
months.  When HCC recurred,  re-treatment was per-
formed depending on patient conditions,  tumor stage 
and background liver function,  according to the same 
clinical indications as for the ﬁrst intervention.
　 Time-ﬁxed model construction. Survival 
duration was calculated from the date of initial treat-
ment to the date of liver-related death.  Examined 
covariates were as follows: nine background factors 
(presence of ascites,  age,  bilirubin,  albumin,  AST,  
ALT,  creatinine,  platelet count,  and prothrombin 
time) and six tumor-related factors (main tumor size,  
tumor number,  presence of portal vein invasion or 
distant metastasis,  AFP,  and DCP).  We conducted 
univariate survival analysis using a Cox proportional 
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hazards model [15] with these covariates at the initial 
treatment.  For continuous variables or category 
variables with 3 values or more,  we prepared multiple 
cut-oﬀ values for each factor and adopted the one with 
the highest likelihood.
　 Factors exhibiting signiﬁcant values in univariate 
analysis were selected to build the model and were 
used for time-ﬁxed multivariate Cox regression analy-
sis.  We built the model consisting of 8 factors where 
the goodness of ﬁt of the model was optimized with the 
best option of the PHREG procedure of SAS 9.1.3.  
We assumed the value of the logarithm hazard corre-
sponding to each factor rounded to 0.5 units as the 
“weighted score (WS)” and summed the score.  The 
integer part of the total score was deﬁned as the 
prognostic index (PI).  When the score was more than 
5,  we considered it to be PI 5.
　 Time-dependent model construction. We 
adopted the method of Murtaugh et al.  to incorporate 
the change in the covariate over time in the model.  In 
this way,  721 survival data points were generated for 
the training group and 465 for the testing group.  
Missing values were estimated from the previously 
recorded value of the variable [16].  The same 9 
background factors and 6 tumor-related factors that 
we adopted in the time-ﬁxed model construction were 
examined.
　 The cut-oﬀ values of each covariate were deter-
mined and used to build a model by the same method 
as that for the time-ﬁxed model construction.
　 Validation. To evaluate the validity of the 
time-ﬁxed and time-dependent models that we built,  we 
applied these models to the testing group.  We exam-
ined conformity between observed prognosis and PI of 
all patients in the testing group and calculated the 
c-index [17].  The c-index is deﬁned as the proportion 
of all usable patient pairs in which the predictions and 
outcome are concordant.
　 The c-indexes and the 95ｵ conﬁdence intervals of 
CLIP scores,  JIS scores,  and Okuda classiﬁcation 
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Table 1　 Baseline characteristics of 563 patients with HCC
Total Training Group (n＝336) Testing Group (n＝227) p-value
Male (%) 407 (72%) 241 (72%) 166 (73%) 0.72
Etiology (B/C/B＋C/other) 82/413/14/54 49/245/9/33 33/168/5/21 1.00
Child-Pugh grade (A/B/C) 395/142/26 240/82/14 155/60/12 0.68
Age at treatment (years)† 65 (23-85) 65 (23-83) 65 (28-85) 0.73
Tumor number (single) 306 (54%) 183 (54%) 123 (54%) 0.95
Main tumor size (mm)† 25 (8-160) 25 (9-160) 25 (8-160) 0.91
Tumor stage (Ⅰ/Ⅱ/Ⅲ/Ⅳ) 145/185/167/65 91/107/98/40 54/78/69/25 0.80
AFP (ng/ml)† 23 (0.5-455,560) 22 (0.5-455,560) 25 (1.4-116,870) 0.76
DCP (mAU/ml)† 23 (0-455,560) 44 (0-410,500) 56 (0-317,000) 0.46
Number of hospitalization† 1 (1-12) 2 (1-12) 1 (1-8) 0.44
Number of liver-related death 218 (38.8%) 123 (36.6%) 95 (41.9%) 0.15
Histologic diﬀerentiation
　Well diﬀerentiated 95 (17%) 55 (16%) 40 (18%)
0.97　Moderately diﬀerentiated 97 (17%) 57 (17%) 40 (18%)
　Poorly diﬀerentiated 15 (3%) 9 (3%) 6 (3%)
　Not examined 356 (63%) 215 (64%) 141 (61%)
Treatment of HCC
　RFA 150 (27%) 94 (28%) 56 (25%)
0.80
　MCT 13 (2%) 8 (2%) 5 (2%)
　PEIT 73 (13%) 49 (15%) 24 (11%)
　Liver resection 129 (23%) 72 (21%) 57 (25%)
　TACE/TAI 131 (23%) 75 (22%) 56 (25%)
　Chemotherapy 49 (8%) 28 (8%) 21 (9%)
　Liver transplantation 8 (1%) 4 (1%) 4 (2%)
Others 10 (2%) 6 (2%) 4 (2%)
†Data are shown as median (range). AFP,  alpha-fetoprotein; DCP,  des-gamma-carboxy prothrombin; RFA,  radiofrequency ablation;  
MCT,  microwave coagulation therapy; PEIT,  percutaneous ethanol injection therapy; TACE,  transcatheter arterial 
chemoembolization; TAI,  transcatheter arterial infusion.
[18] were calculated in the testing group,  and the 
precision of the prognostic values was compared with 
that obtained with our models.  SAS 9.1.3 and JMP 
7.0.2 (SAS Institute) were used for all analyses.
Results
　 Patient background. The background factors 
of 563 patients are shown in Table 1.  The average 
age was 64.4 years old.  Four hundred and thirteen 
patients (73ｵ) were positive for hepatitis C virus 
antibody,  and 82 patients (15ｵ) were positive for 
hepatitis B virus antigen.  No diﬀerence in values was 
observed between the training and testing groups.  
The 1-year,  3-year,  and 5-year survival rates were 
88ｵ,  67ｵ,  and 52ｵ,  respectively.
　 Time-ﬁxed model. Based on the univariate 
analysis,  the presence of ascites,  bilirubin,  albumin,  
AST,  ALT,  prothrombin time,  main tumor size,  
tumor number,  portal vein invasion,  distant metasta-
sis,  AFP,  and DCP were closely related to survival.  
The 8 selected factors and WS values were as 
follows: main tumor size (WS＝1),  portal vein inva-
sion (WS＝1.5),  tumor number (WS＝1),  distant 
metastasis (WS＝2),  AFP (WS＝0.5),  bilirubin 
(WS＝0.5),  albumin (WS＝0.5),  and prothrombin 
time (WS＝1) (Table 2).  The 1-year survival rates in 
PI 0,  1,  2,  3,  4,  and 5 of the training group were 
100ｵ,  97ｵ,  96ｵ,  75ｵ,  20ｵ,  and 10ｵ,  and the 
5-year survival rates were 69ｵ,  70ｵ,  43ｵ,  19ｵ,  
0ｵ,  and 0ｵ,  respectively.  The survival curves for 
each PI are shown in Fig. 1.  With the exception of 
that between PI0 and PI1,  statistically signiﬁcant 
diﬀerences were found between each survival period.
　 Time-dependent model. Based on the uni-
variate analysis,  the factors related to survival were 
the presence of ascites,  bilirubin,  albumin,  AST,  
prothrombin time,  main tumor size,  tumor number,  
portal vein invasion,  distant metastasis,  AFP,  and 
DCP.  From the results of the multivariable analysis,  
a prognosis model consisting of main tumor size (WS
＝0.5),  portal vein invasion (WS＝0.5),  tumor num-
ber (WS＝1.5),  distant metastasis (WS＝1.5),  AFP 
(WS＝0.5),  DCP (WS＝1),  bilirubin (WS＝0.5),  
and albumin (WS＝0.5) was made (Table 3).  The 
1-year survival rates in PI 0,  1,  2,  3,  4,  and 5 of the 
training group were 99ｵ,  92ｵ,  76ｵ,  39ｵ,  15ｵ,  
and 0ｵ,  and the 5-year survival rates were 84ｵ,  
75ｵ,  31ｵ,  0ｵ,  10ｵ,  and 0ｵ,  respectively.  The 
survival curves for each PI are shown in Fig. 2.  
Between all pairs of 2 adjacent prognostic indices,  
statistically signiﬁcant diﬀerences of survival were 
observed.  Median survival times (MST) and 95ｵ 
conﬁdence intervals of survival duration of PI 1,  2,  
3,  4,  and 5 were 7.9 years (5.0-18.0 years),  2.5 
years (1.6-4.9 years),  0.7 years (0.4-1.4 years),  0.4 
years (0.1-0.6 year),  and 0.2 years (0.1-0.4 year),  
respectively.
　 Model ﬁtness. We applied conventional CLIP 
scores,  JIS scores,  Okuda classiﬁcations,  and our 
prognostic models to the testing group,  and compared 
the goodness of ﬁt of the models in terms of the 
c-index.  Regarding our time-ﬁxed and time-dependent 
model,  CLIP scores,  JIS scores,  the Okuda classiﬁ-
cation,  and survival curves in the testing group are 
shown in Fig. 3(A)-(E).  The c-indexes and the 95ｵ 
conﬁdence intervals of our time-ﬁxed and time-depen-
dent model,  CLIP scores,  JIS scores,  and Okuda 
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Table 2　 Time-ﬁxed model
Factor β SE RR 95%CI p-value Weighted score
Main tumor size (30mm＜ ) 0.79 0.24 2.20 1.39-3.50 ＜0.001 1　
Portal vein invasion (vp2＜) 1.65 0.33 5.19 2.75-9.80 ＜0.001 1.5　
Tumor number (3＜) 1.24 0.23 3.45 2.18-5.46 ＜0.001 1　
Distant metastasis (present) 1.78 0.43 5.92 2.55-13.71 ＜0.001 2　
AFP (400ng/ml＜) 0.53 0.27 1.70 1.01-2.86 　0.045 0.5　
Serum bilirubin (1.0mg/dl＜) 0.12 0.22 1.13 0.73-1.74 　0.587 0.5†
Serum albumin (＜3.5g/dl) 0.61 0.22 1.84 1.19-2.83 　0.006 0.5　
Prothrombin time (＜80%) 0.86 0.23 2.34 1.51-3.71 ＜0.001 1　
†Because the logarithm hazard of the serum bilirubin was less than 0.25,  we deﬁned 0.5,  which was the minimum of the score,  as the 
weighted score of serum bilirubin.
β,  parameter of each factor; SE,  standard error of β; RR,  risk ratio; 95%CI,  95% conﬁdence interval of RR.
classiﬁcation are shown in Table 4.  The c-index of our 
time-dependent model was higher than that of all of the 
time-ﬁxed prognostic models,  indicating that the 
prognostic estimation of the time-dependent model was 
the best.
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Fig. 1　 Survival rate in each PI of the time-ﬁxed model for the 
training group.  The 1-year survival rates in PI 0,  1,  2,  3,  4,  and 5 
of the training group were 100%,  97%,  96%,  75%,  20%,  and 
10%,  and the 5-year survival rates were 69%,  70%,  43%,  19%,  
0%,  and 0%,  respectively.  With the exception of that between PI0 
and PI1,  statistically signiﬁcant diﬀerences were found between 
each survival period.
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Fig. 2　 Survival rates in each PI of the time-dependent model for 
the training group.  The 1-year survival rates in PI 0, 1,  2,  3,  4,  
and 5 of the training group were 99%,  92%,  76%,  39%,  15%,  
and 0%,  and the 5-year survival rates were 84%,  75%,  31%,  0%,  
10%,  and 0%,  respectively.  Between all pairs of two adjacent 
prognostic indices,  statistically signiﬁcant diﬀerences of survival 
were observed.
Table 3　 Time-dependent model
Factor β SE RR 95%CI p-value Weighted score
Main tumor size (30mm＜) 0.48 0.24 1.62 1.01-2.59 　0.045 0.5
Portal vein invasion (vp1＜) 0.46 0.26 1.58 0.95-2.65 　0.080 0.5
Tumor number (3＜) 1.61 0.23 5.00 3.21-7.78 ＜0.001 1.5
Distant metastasis (present) 1.39 0.28 4.02 2.35-6.89 ＜0.001 1.5
AFP (1,000ng/ml＜) 0.63 0.23 1.88 1.20-2.95 　0.006 0.5
DCP (1,000ng/ml＜) 0.94 0.25 2.56 1.57-4.16 ＜0.001 1
Serum bilirubin (1.0mg/dl＜) 0.70 0.22 2.00 1.31-3.06 　0.001 0.5
Serum albumin (＜3.5g/dl) 0.67 0.24 1.96 1.24-3.11 　0.004 0.5
β,  parameter of each factor; SE,  standard error of β; RR,  risk ratio; 95%CI,  95% conﬁdence interval of RR.
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Fig. 3　 Survival rate in each prognostic score of the time-ﬁxed model and our time-dependent model for the testing group.  Our time-ﬁxed 
model (A),  our time-dependent model (B),  CLIP scores (C),  JIS scores (D),  and Okuda classiﬁcation (E) are shown.
Discussion
　 The utilization of time-dependent covariates has 
been shown to help in predicting the prognosis of 
several diseases.  We used time-dependent covariates 
for constructing a prognostic model of HCC and dem-
onstrated its superiority in this study.  The c-indexes 
of our time-dependent model and the time-ﬁxed model 
were higher than those of pre-existing time-ﬁxed 
scores such as CLIP scores,  JIS scores,  and Okuda 
stage.
　 One of the characteristics of our time-dependent 
model is that the weight of tumor-related factors is 
higher than that in other models,  including our time-
ﬁxed model.  Among the eight factors constituting the 
time-dependent model,  6 are tumor-related.  Of the 6.5 
total points for the total weighted score,  5.5 are for 
tumor-related factors.
　 The weights of tumor-related factors in 3 conven-
tional prognostic models were diﬀerent.  The tumor-
related factors in the CLIP scoring system are tumor 
morphology,  AFP and portal vein thrombus,  so the 
weight is 4 of 6.  There is only one tumor-related fac-
tor,  tumor size,  in the Okuda staging system out of 
four covariates.  The JIS scoring system consists of 2 
equally weighted factors,  which are the TNM classi-
ﬁcation and Child-Pugh grade,  meaning that half of the 
score is from tumor-related factors.  Among the 3 
conventional prognostic models,  the CLIP score was 
superior to the 2 other models in terms of its ability 
to estimate prognosis.  Our time-ﬁxed model consists 
of 5 tumor-related factors out of 8 total factors,  and 
the c-index is very similar to that of the CLIP score.
　 These results indicate that a higher weight of 
tumor-related factors in prognostic models may 
increase the ability to predict prognosis in this study 
population and might be one of the reasons for the 
striking superiority of our time-dependent model.
　 Liao et al.  [10] investigated 108 patients with 
HCC smaller than 5cm and built a time-dependent 
prognostic model with a time-dependent Cox regres-
sion model.  The method used was very similar to that 
used in the present study and also suggested the supe-
riority of the adoption of time-dependent factors for 
predicting prognosis.  The prognostic model in this 
previous study consists of 6 factors: AFP,  serum 
albumin,  AST,  serum bilirubin,  alkaline phosphatase 
(ALP),  and prothrombin time.  They selected only 
AFP as a tumor-related factor.  They considered 
other tumor-related factors such as tumor number and 
diameter only as baseline parameters and did not 
examine change over time.  One of the possible expla-
nations for the diﬀerence in covariates between their 
study and our model is the diﬀerence in the study 
population.  They dealt with only HCC treated with 
PEIT,  meaning that they seemed to treat HCC cura-
tively and that the eﬀects of tumor factors such as 
tumor size decreased and were excluded from the 
17Time-Dependent Prognostic Model for HCCFebruary 2011
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Fig. 3　 Survival rate in each prognostic score of the time-ﬁxed 
model and our time-dependent model for the testing group.  Okuda 
classiﬁcation (E) are shown.
Table 4　 C-index of models
c-index (95%CI)
Time-ﬁxed Time-dependent
Our model 0.775 (0.477-0.990) 0.870 (0.603-1.000)
CLIP 0.741 (0.432-0.975) ―
JIS 0.727 (0.418-0.966) ―
Okuda 0.609 (0.226-0.946) ―
CLIP,  Cancer of the Liver Italian Program; JIS,  Japan Integrated 
Staging Score; Okuda,  Okuda staging system; 95%CI,  95% conﬁ-
dence interval.
model.  In contrast,  the patients in our study were not 
limited to those with small HCC.
　 The superiority of the time-dependent model for 
prediction of the prognosis of HCC was clearly 
demonstrated; however,  there were some limitations 
to this study.  There are several other factors associ-
ated with prognosis of HCC such as lens culinaris 
agglutinin-reactive fraction of alpha-fetoprotein 
(AFP-L3).  The adoption of these factors may result 
in the construction of a better model.
　 The hepatitis C virus is a maximal pathogenesis 
factor of HCC,  and the most of patients of this study 
are transmitted to the virus.  The contribution of 
mutations in the hepatitis C virus core gene has been 
reported to be a virus side factor associated with liver 
carcinogenesis [19].  Also,  single nucleotide poly-
morphisms (SNPs) of IL28B have been reported as a 
host factor involved in the treatment of chronic hepa-
titis C [20].  The adoption of genetic information from 
the virus and the host may result in the construction 
of a more correct model in the future.
　 Because this was a study based at a single institu-
tion,  it has not been shown that we can extrapolate 
our results to other institutions or countries.  The skill 
in RFA and selective TACE diﬀer,  and patient back-
grounds also diﬀer.  The index might be too precise to 
apply to all cases.  But there is also merit in the study 
being limited to a single institution.  Because blood 
tests and imaging studies were performed according to 
the same surveillance algorithm,  the lead-time bias 
that inﬂuenced the model was minimized.  As for all 
the prognostic factors,  minor modiﬁcations depending 
on individual clinical circumstances are advisable for 
obtaining better predictive ability.
　 The original point in this study is that we used 
time-dependent covariates in a model based on the 
premise that prognosis changes drastically with the 
state at recurrence.  We can predict prognosis even if 
HCC recurs and tumor stage and liver residual func-
tion change using this time-dependent model.  The 
potential to estimate the prognosis of HCC is better 
than that of the traditional time-ﬁxed models.  More 
studies to verify its eﬀectiveness for diﬀerent popula-
tions are needed to conﬁrm that the index can be 
widely used.
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